Latest & Greatest

Latest & Greatest

Recent developments in the field of hematology/oncology, including drug approvals, policy updates, and clinical trial results

Federal Trade Commission Wins Case Against Predatory Publisher

OMICS International, which publishes nearly 700 scientific journals, was ordered to pay $50.1 million in damages for engaging in “predatory publisher” tactics. The ruling...
gene therapy

Europe Poised to Approve Gene Therapy for Beta Thalassemia

Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended that the European Medicines Agency (EMA) approve Bluebird Bio’s LentiGlobin gene-therapy product for patients...

U.S. CRISPR Study in Humans Gets Underway

The first patients enrolled in a trial of CRISPR-based gene editing at the University of Pennsylvania have been treated with the powerful – and...
stem cell

FDA and State Authorities Renew Efforts Against Dangerous Stem Cell Clinics

The U.S. Food and Drug Administration (FDA) and New York’s attorney general have announced new policing strategies against for-profit clinics that offer expensive and...

FDA Halts Trials of Venetoclax for Myeloma

The U.S. Food and Drug Administration (FDA) has issued a warning to health-care professionals and clinical investigators about the risks associated with the investigational...

FDA’s ODAC Rejects Selinexor for Myeloma

In an 8-to-5 vote, the U.S. Food and Drug Administration's (FDA’s) Oncologic Drug Advisory Committee (ODAC) decided against recommending accelerated approval of selinexor for...

Biomedical Research Community Concerned About Cuts in Proposed 2020 Budget

On March 11, President Donald Trump released his proposed fiscal year 2020 budget, called “A Budget for a Better America,” that includes a substantial...

FDA Alerts Patients About Blood Clot and Mortality Risk With Tofacitinib

The U.S. Food and Drug Administration (FDA) has issued a Safety Announcement for the Janus kinase (JAK) inhibitor tofacitinib after a required postmarketing trial...

Scott Gottlieb Resigns as FDA Commissioner

On March 5, U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, announced his resignation, citing a desire to spend more time with...

Ibrutinib and Obinutuzumab Combo Granted Approval for CLL/SLL

The U.S. Food and Drug Administration (FDA) approved the combination of ibrutinib and obinutuzumab for the treatment of patients with treatment-naïve chronic lymphocytic leukemia/small...
Advertisement

Current Issue

October 2019, Volume 5, Issue 12

This issue highlights the unintended consequences of fighting the nation’s opioid epidemic, considers the optimal frontline regimen for myeloma, and more.